Telerobotic surgery is transitioning from isolated demonstrations to broader clinical and regulatory development, according to a recent MedTech Dive report. The article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s progress and the regulatory and infrastructure challenges surrounding remote surgery. It highlighted SS Innovations International (NASDAQ: SSII) alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
SS Innovations CEO Dr. Sudhir Srivastava, a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. The company reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
These figures underscore the commercial momentum behind telerobotic surgery, a field that could reshape how surgical expertise is delivered across geographies. By enabling remote procedures, hospitals in underserved regions may gain access to specialized care without requiring patients to travel. For SS Innovations, the growing procedure volume and geographic footprint provide real-world evidence that could support regulatory submissions. The company is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand into additional international markets. Success in these efforts would position SS Innovations in a market currently dominated by larger players, but where telesurgery capabilities could serve as a key differentiator.
The broader implications extend beyond SS Innovations. As telerobotic surgery gains ground, regulators, healthcare providers, and infrastructure planners will need to address questions around latency, data security, and liability. The MedTech Dive article noted that while the technology is advancing globally, U.S. adoption may hinge on clear regulatory pathways and robust telecommunications networks. SS Innovations’ experience with long-distance operations could inform those discussions. The company’s newsroom at https://ibn.fm/SSII provides ongoing updates.
MissionIR, a communications platform, distributed the update. It operates as part of a Dynamic Brand Portfolio under IBN, offering services such as InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. These channels help companies like SS Innovations reach investors and industry stakeholders. As telerobotic surgery moves toward mainstream adoption, SS Innovations’ progress and regulatory milestones will be closely watched, with potential ramifications for the competitive landscape of surgical robotics.
